Georgiamune, a Gaithersburg, Maryland-based clinical-stage biotech with roughly 30 employees, is reported to be raising approximately $93 million in Series B financing to advance its cancer and autoimmune disease programs.
About Georgiamune
Georgiamune Inc. is a private, science and discovery clinical stage immunotherapeutic biotechnology company focused on reprogramming immune signaling pathways to redirect the immune system to fight diseases. Unique approaches to re-establishing immune balance and groundbreaking scientific discoveries have led to the development of pioneering immune therapeutics for cancer and autoimmune diseases.
